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Abstract  
Translation mechanisms at different stages of the cell cycle have been studied for many years, 
resulting in the dogma that translation rates are slowed during mitosis, with cap-independent 
translation mechanisms favoured to give expression of key regulatory proteins. However, such cell 
culture studies involve synchronisation using harsh methods, which may in themselves stress cells 
and affect protein synthesis rates. One such commonly used chemical is the microtubule de-
polymerisation agent, nocodazole, which arrests cells in mitosis, and has been used to demonstrate 
that translation rates are strongly reduced (down to 30% of that of asynchronous cells). Using 
synchronised HeLa cells released from a double thymidine block (G1/S boundary), or the Cdk1 
inhibitor, RO3306 (G2/M boundary), we have systematically re-addressed this dogma. Using FACS 
analysis and pulse-labelling of proteins with labelled methionine we now show that translation rates 
do not slow as cells enter mitosis. This study is complemented by studies employing confocal 
microscopy which show enrichment of translation initiation factors at the microtubule organising 
centres, mitotic spindle and midbody structure during the final steps of cytokinesis, suggesting that 
translation is maintained during mitosis. Furthermore, we show that inhibition of translation in 
response to extended times of exposure to nocodazole reflects increased eIF2α phosphorylation, 
disaggregation of polysomes, and hyperphosphorylation of selected initiation factors, including 
novel Cdk1-dependent N-terminal phosphorylation of eIF4GII. Our work suggests that effects on 
translation in nocodazole arrested cells might be related to those of the treatment used to 
synchronise cells rather than cell cycle status. 
  
Introduction 
Protein synthesis is carried out in three stages (initiation, elongation and termination), with the 
initiation stage of translation generally accepted as a major site of regulation of gene expression.1-6 
This pivotal role reflects the regulated binding of mRNA to the ribosome, facilitated by the assembly 
of eIFs (eukaryotic initiation factors) into a multi-protein complex known as eIF4F (composed of 
eIF4E, eIF4A and eIF4G) which associate with the 7-methylguanylate (m7G) cap structure at the 5’ 
end of the mRNA. eIF4G is expressed as two paralogues in mammalian cells, eIF4GI and eIF4GII. 
Although initial reports suggested eIF4GI and eIF4GII were interchangeable,7 over-expression of the 
eIF4GII paralogue in an eIF4GI knockdown background was unable to restore translation to the same 
extent as eIF4GI.8 
    In turn, the activity of the eIF4F complex is regulated by both phosphorylation and the inherent 
structural properties of the recruited mRNA.1, 4, 6 The formation of the eIF4F complex reflects the 
regulated availability of eIF4E to participate in initiation, a process controlled by a number of general 
and mRNA-specific regulatory proteins. Using a conserved motif, 4E-BPs (eIF4E-binding proteins) 
compete with the eIF4Gs for a common surface on eIF4E and inhibit eIF4F assembly. The regulated 
association of 4E-BPs with eIF4E is acutely modulated by multi-site phosphorylation dependent upon 
mammalian target of rapamycin complex 1 (mTORC1) signalling,2, 5 effectively integrating signals 
from mitogens and nutrients with the translational apparatus.2, 3  In addition to modification of the 
eIF4 family of proteins, phosphorylation of the α-subunit of the canonical initiation factor eIF-2 has 
been shown to be increased at G2/M.
9 This phosphorylation has been shown to have a permissive 
effect on the efficiency of cap-independent initiation of translation at two cell cycle-dependent 
internal ribosome entry sites (IRESs), thereby mediating specific mRNA translation at this phase of 
the cell cycle.9 
    Work over a number of years has suggested that the rate of protein synthesis varies throughout 
the cell cycle.10-12 In HeLa cells arrested in mitosis using colcemid, cap-dependent, but not IRES-
mediated, translation initiation was impaired along with a dephosphorylation of eIF4E.13 In 
nocodazole-arrested HeLa cells, 4E-BP1 was shown to be in a more hypophosphorylated state, 
interacting strongly with eIF4E, decreasing eIF4F complex levels.11 The same study showed that 
eIF4GII was hyperphosphorylated during nocodazole treatment of cells which correlated with a 
decrease in its binding to eIF4E. In contrast, in HeLa cells synchronised and released from a 
sequential thymidine and aphidicolin block, phosphorylation of 4E-BP1 was increased at Thr-70 by 
the cyclin-dependent kinase, Cdk1, with phosphorylation of this site being permissive for Ser-65 
phosphorylation.14  
    Using synchronised HeLa cells incubated with nocodazole, the Cdk1 inhibitor, RO3306, or released 
from a double thymidine block, we have systematically re-addressed whether rates of protein 
synthesis are changed during mitosis and how this correlates with initiation factor phosphorylation. 
The work described here indicates that exposure of cells to nocodazole promotes increased eIF2α 
phosphorylation and disaggregation of polysomes, characteristics of an inhibition of initiation. 
However, this was not observed with cells released from a G1/S block using the double-thymidine 
approach. Furthermore, we have teased apart some of the phosphorylation events that occur in 
response to nocodazole, and present here a reappraisal of how initiation factor complexes are 
effected in response to this treatment.  
Results 
Translation rates are maintained throughout the cell cycle, and initiation factors are associated 
with components of the tubulin cytoskeleton during mitosis 
Double thymidine block was used to synchronise exponentially growing HeLa cells at the G1/S phase 
border. Cells were then released from this block and the nuclear content analysed by propidium 
staining and flow cytometry analysis showing that a cycle was completed within 20 hours (Figure 1A). 
The majority of mitosis was observed to occur between 8 and 11 hours post-release. These results 
are in agreement with previous work.15 In parallel experiments, the incorporation of [35S] 
Methionine into precipitable protein was measured for the 30 minutes prior to harvest in order to 
gauge whether there was a decrease in protein synthesis rate in cells going through M phase. While 
translation rates did fluctuate during the cell cycle, there was no decrease observed at any of the 
time points where the majority of cells were undergoing mitosis (Figure 1B). In comparison, in cells 
that were synchronised with thymidine, released then incubated with nocodazole, there was a 
robust decrease in translation to around ~30% of that of asynchronous cells, in agreement with 
previous work.16 
Immunoblotting of cell extracts showed that the levels of the cell cycle markers Cyclin B1 and 
Survivin increased and decreased as predicted throughout the timecourse (Figure 1C). When 
determining the influence of the cell cycle stages on members of the translation initiation factor 
machinery, there were no changes in levels of components of the eIF4F complex (eIF4GI, eIF4A and 
eIF4E) and no increased phosphorylation of eIF2α was observed. There was an upward shift in 
mobility of 4E-BP1 in cells in early G1 and immediately post M phase (12-14 hours post release), 
suggesting an increase in phosphorylation. According to models of translational control, these 
results all point to a generally favourable environment for translation to proceed. 
The results from Figures 1B and C indicate that, rather than there being a reduction in protein 
synthesis associated with passage into mitosis, translation is maintained at a relatively consistent 
level throughout the cell cycle. We and others have previously shown that a subpopulation of 
components of the initiation factor machinery are localised to the nucleus.17 We therefore 
embarked on confocal microscopy experiments to examine how these proteins localise in cells in 
which the nuclear membrane undergoes breakdown,18 thus removing the physical barrier between 
the cytoplasm and nucleoplasm. We examined synchronised cells that were proceeding through 
mitosis (Figure 2), staining cells for a component of the translation machinery (eIF4GI, PABP, eIF4E,  
4E-BP1 or ribosomal protein S6) alongside α-tubulin and DNA, the definitive morphologies of which 
could be used to define the various characteristic stages. At each stage co-localisation of each 
component was observed with the tubulin cytoskeleton, implying that there may be some ongoing 
translation localised to this important component of the cell. This perhaps aids in the synthesis of 
further tubulin, or other components (e.g. chromosomal passenger proteins) which are required for 
efficient mitosis. 
Synchronisation in M phase with nocodazole inhibits translation rates and leads to robust 
phosphorylation of key translation factors 
Given that our work showed that there was unlikely to be any inhibition of translation in cells 
transiting through mitosis, we returned to those which had undergone treatment with nocodazole, 
to determine the underlying mechanisms of the observed reduction in protein synthesis (Figure 1B). 
FACS analysis showed the expected peak of cells arrested in G2/M when compared to cells 
maintained in an asynchronous state (Figure 3A), and sucrose density gradients show that 
nocodazole treatment leads to a reduction in polysomes, a further confirmation of the inhibition of 
protein synthesis (Figure 3B). Extracts from asynchronous cells or those having undergone 
thymidine/nocodazole synchronisation showed that there was a strong phosphorylation of the alpha 
subunit of eIF2 on Ser 51 (Figure 3C), confirming the work of others.16 This post-translational 
modification inhibits the eIF2B guanine nucleotide exchange factor, which prevents the recycling of 
eIF2 from a GDP to a GTP bound state, thus preventing ternary complex formation (eIF2·Met-
tRNAi·GTP), thus inhibiting further rounds of translation initiation. Other modifications of translation 
initiation factors were observed, with a retarded migration observed of eIF4GI, eIF4GII and of some 
of the 4E-BP1 population (Figure 3C). The maintenance of a proportion of 4E-BP1 in a 
hypophosphorylated (termed “α”) state shows another situation which would be likely to inhibit 
translation. This phosphor-form of the protein is able to bind to and sequester eIF4E and inhibit the 
interaction of this cap-binding protein with the eIF4G proteins, which act as molecular “scaffolds” 
onto which a number of other factors bind. However, we also observed that around 70% of the 4E-
BP1 migrated higher than the standard phosphor-forms of the proteins, reflecting modification over 
and above those already established. This modification was not prevented by preincubation of cells 
with the mTOR inhibitor RAD001 (Figure S1). We used our low percentage SDS-PAGE method19 to 
enable delineation of eIF4G isoforms which arise through alternative translation initiation from 
either different AUGs (in the case of eIF4GI20, 21) or a CUG and AUG (eIF4GII8) and therefore differ at 
their N-termini. The shift in migration was observed in all the isoforms, (Figure 3C) suggesting that 
no one eIF4G isoform is subjected to differential regulation. Both these factors, and 4E-BP1 are 
known phosphoproteins, so we next analysed whether the migratory changes were due to 
phosphorylation. 
Extracts from asynchronous or nocodazole treated cells were prepared, and then treated with 
bacteriophage lambda protein phosphatase (Figure 3D). In all cases, the nocodazole-dependent 
changes in migration or phosphorylation were either greatly reduced or completely abrogated, 
suggesting that phosphorylation is the post-translational modification underlying these observations. 
In the case of eIF4GII, it was also observed that there is an underlying phosphorylation in 
asynchronously maintained cells, which is likely to be due to phosphorylation at alternative sites to 
those modified in this treatment.22 
Robust phosphorylation of eIF2α and 4E-BP1 does not occur following release from G2/M block or 
with reduced incubation with nocodazole 
To investigate the nocodazole-dependent phosphorylation of initiation factors in more detail, we 
employed an alternative mechanism to arrest cells at the G2/M border. Phosphorylation of key 
substrates by the Cdk1/cyclin B complex acts as a trigger for the commitment to mitosis, and so the 
reversible cell-permeable small molecule Cdk1 inhibitor RO330623 was employed, as it acts in an 
independent manner to those like nocodazole which act on microtubule dynamics. In our experience, 
we have struggled to release cells from the nodazole-induced arrest, but this is issue is not the case 
when using RO3306. Therefore, following removal of this inhibitor from the cell medium, the cell 
cycle status was assayed by FACS in comparison to asynchronous cells, or those arrested by 
thymidine nocodazole block (Figure 4A), and translation rates measured as before (Figure 4B), albeit 
with a shorter 15 minute pulse of [35S] methionine prior to harvest. While we did observe some 
inhibition of protein synthesis in the cells treated with RO3306, this was not as strong as that 
observed with nocodazole and we measured no further reduction in translation rates as cells 
progressed through mitosis. Analysis of extracts prepared from these cells (Figure 4C) showed that 
there was no shift in migration of eIF4GI, only a slight phosphorylation of eIF2α and a transient 
limited migration of 4E-BP1 to the upper forms. This suggests that any of the changes of signalling 
events to these proteins are only limited or transitory, but exposure to nocodazole itself maybe 
creating a situation where the modifications are maintained for too long, thus allowing a state of 
reduced translation to develop. 
To further determine the effects of sustained incubation with nocodazole, we again synchronised 
cells by double thymidine block, and then post-release incubated them without nocodazole or by 
adding nocodazole at different times. This would induce the arrest as usual, but the nocodazole 
would only have been present for less time than in the standard protocol. FACS analysis showed that 
the nocodazole induced the expected arrest, whether added at an initial or later time after release 
of the thymidine block (Figure 4D). Pulse labelling of cells with [35S] methionine prior to harvest 
showed that there was only a limited inhibition of protein synthesis at the last time point (Figure 4E), 
by which point some of the cells which would have otherwise completed mitosis would have been 
arrested for around 4 hours, rather than the 20 hours utilised in the standard protocol. It is therefore 
not surprising that the modifications of eIF2α and 4E-BP1 were also only observed at later 
timepoints in these cells, and at a limited level as determined by immunoblotting (Figure 4F). 
In addition to the four mTORC1-dependent phosphorylation sites of 4E-BP1 identified at Thr 37, 
Thr 46, Ser 65 and Thr 70,24, 25 other phosphorylation sites were postulated at Ser 83 and Ser 112.26, 
27 Therefore, we attempted to identify if these were the sites modified following nocodazole 
treatment. A cDNA corresponding to the open reading frame of 4E-BP1 was obtained by RT-PCR of 
HEK293 cell RNA and subcloned into a vector which fused a myc-tag to the N-terminus and 3 copies 
of the FLAG tag to the C-terminus. This vector was then subjected to site-directed mutagenesis to 
convert the serines at 83 and 112 to alanines, either singly or together. The wild-type vector and the 
three mutated variants were then transfected into HeLa cells which were incubated with or without 
nocodazole (Figure 4G). Although it is not as obvious as observed with the endogenous protein 
(possibly due to the overexpression of the exogenous tagged 4E-BP1) there is an upward shift in 
response to nocodazole with the WT and S112A variants. However, the movement of S83A is less 
evident, perhaps indicating that this residue is a further site of phosphorylation in cells treated with 
nocodazole. Previous work has shown that 4E-BP1 can be phosphorylated by Cdk1 in vitro14 and it is 
possible that a further threonine residue could be a subsequent target following phosphorylation at 
Thr 70 by this kinase. Given these results, Thr 82 could perhaps be such a site. To this end we 
created further mutants (T82A and T82A/S83A) to examine if the nocodazole dependent 
modifications were abrogated. To aid in the identification of the phosphoforms of both endogenous 
and exogenous proteins, the membrane was probed with both murine anti-FLAG and leporine anti-
4E-BP1, which enabled us to visualise the migration using appropriate species-specific fluorescently 
tagged secondary antibodies. Our results (Figure 4H, upper panel) show that Thr 82 is not likely to be 
a phosphosite as the upward shift is still observed in T82A (compare lanes 4 and 6). However, the 
relative lack of a shift in the T82A/S83A mutant does again confirm that while Ser 83 may be the 
residue modified in the presence of nocodazole, or be modified in tandem with Thr 82, but neither 
of these is the major site of phosphorylation. The large shift observed in the endogenous 4E-BP1 
could indicate that nocodazole treatment affects a pair of phosphosites, and it is a consequence of 
overexpressing exogenous 4E-BP1 that prevents us observing these modifications to their full extent. 
Indeed, probing the membrane with an anti-4E-BP1 antibody shows the substantial expression of 
exogenous protein versus the endogenous (Figure 4H, lower panel). 
The phosphorylation of eIF4GII maps to a novel N-terminal site 
Previous work has established the presence of three serum sensitive serine phosphorylation sites on 
eIF4GI (Figure 5A) at 1148, 1188 and 1232 (using numbering for the longest eIF4GI isoform,20, 21 with 
PKCα responsible for a further phosphorylation at Ser 118628). In addition, CAMK1 has been 
described as phosphorylating eIF4GII (Figure 5D) in a similar C-terminal region of the molecule 
(Ser 130822), using the numbering from our work which extended the N-terminus from a CUG 
initiation codon.8 
To delineate the sites of phosphorylation observed in nocodazole treatment, we created cDNAs 
corresponding to regions of both proteins. Firstly, eIF4GI was separated into fragments 
corresponding to those that arise from caspase-directed cleavage of the protein during apoptosis. 
This separates the molecule into three “FAGs”,29-31 with each corresponding cDNA inserted into the 
same N-myc, C-3xFLAG vector as before. Each vector was then transfected into HeLa cells and 48 
hours after transfection, the cells were incubated with or without nocodazole. Figure 5B shows that, 
there was a small, reproducible shift in only the N-terminal fragment (N-FAGf, lanes 1 and 2) and 
also more of the upper band in the doublet from C-FAG expressing cells. As two of the three known 
phosphoserines on eIF4GI are in this latter fragment, we concentrated our efforts on the N-FAGf, 
splitting it into further fragments, and carrying out experiments in a similar manner (Figure 5C). 
There was a slight shift in the f-QIAP and e-QIAP fragments, suggesting there may be a novel 
phosphorylation site between amino acids 41 and 147 (compare lane 1 with 2, and 3 with 4). 
However, this phosphorylation does not appear to be as robust as that observed in the full length 
protein and implies either that the protein must be intact or, more likely, that there are multiple 
sites present on eIF4GI and only when phosphorylated together is migration sufficiently retarded. 
Our focus then turned to eIF4GII, with the N-terminus of this protein studied by again making cDNAs 
for insertion in the epitope-tagged vector (Figure 5D). In this case, there was a much clearer 
response to nocodazole treatment (Figure 5E), with a clear shift in migration of the MSGG-EELS (311-
688) fragment (compare lanes 7 and 8). To map the site of modification, further fragments were 
constructed and examined in Figure 5F. While there was a perceptible shift in STVP-EELS, there was a 
much more obvious retardation of MSGG-AAPT (311-435) in nocodazole-treated cells (compare 
lanes 4 and 5). This subfragment was then subjected to immunoprecipitation by virtue of the C-
terminal 3xFLAG tag, allowing us to examine the uppermost migrating species by mass spectroscopy 
and identify the site of modification. 
Phosphorylation of eIF4GII occurs at two sites, with Cdk1 likely to be the kinase responsible for 
their modification 
Mass spectrometric analysis of peptides generated from the MSGG-AAPT fragment identified two 
novel phosphorylation sites at Ser 384 and Ser 392 (Figure S2). These sites were aligned to the eIF4GI 
sequence (Figure 6A), which shows that they lie in a region of poor conservation and are hence 
unique to this paralogue. However, it is interesting to note that Ser 384 is a glutamic acid in eIF4GI 
which suggests that the phosphorylation of this residue shifts the charge in this region of eIF4GII 
closer to that of eIF4GI. Our first task after making this identification was investigating whether 
alanine mutants of either of these sites would abrogate the nocodazole-dependent shift. Therefore 
site-directed mutagenesis was carried on one, the other, or both sites and the migration of these 
mutants and the wild type MSGG-APPT fragment were assayed as before (Figure 6B). The shift is no 
longer observed, but only in the double mutant (S384/392A), implying that both sites need to be 
phosphorylated to cause the shift, but there is no preference as to the order of modification. 
Bioinformatic analysis using GPS 2.1.232 of the novel eIF4GII phosphorylation sites indicated that the 
most likely kinases responsible were Cdk1 and p38 MAPK. An experiment was therefore set up to 
investigate whether inhibitors of either kinase would abolish the nocodazole-dependent shift (Figure 
6C). The modification was still evident in cells treated with the p38 MAPK inhibitor SB202190, but 
was lost in those treated with nocodazole and RO3306, the inhibitor of Cdk1. As the latter 
compound causes a synchronisation of the cells prior to the arrest induced by nocodazole treatment 
this result is perhaps not surprising. It therefore indicates that Cdk1 may be influencing the 
phosphorylation of eIF4GII either directly or indirectly, however this experiment does not offer 
definitive proof.  
In vitro kinase assays were therefore undertaken to allow the direct phosphorylation of the MSGG-
APPT fragment, which had been immunoprecipitated from asynchronous cells. In a “cold” kinase 
assay (Figure 6D), there is a slight mass increase in the upper band of the MSGG-AAPT fragment 
(compare lanes 1 and 2), giving direct evidence that Cdk1 is indeed the kinase responsible for 
phosphorylation of eIF4GII. However, in the context of this experiment the phosphorylation is 
nowhere near as robust as that observed with the same fragment expressed in HeLa cells exposed to 
nocodazole (lane 4). 
Having confirmed the presence of novel phosphorylation sites in the N-terminus of eIF4GII, we 
finally wished to determine how they influenced the binding capacity of this scaffold protein in the 
context of the full length protein. The double S384/392A mutation was introduced into a vector 
which contained the full eIF4GII open reading frame arising from our recently identified CUG 
initiation codon, fused with a myc-tag at the N-terminus. This tag was then used to co-
immunoprecipitate wild type or mutant eIF4GII from extracts from cells treated with or without 
nocodazole (Figure 6E). Extract from untransfected cells was also subjected to immunoprecipitation 
to ensure that any eluted proteins were present due to interaction with eIF4GII, not the agarose 
resin (lane 8). Due to the conditions of the assay, it was not possible to identify any eIF4A in the 
immunoprecipitation eluate, but PABP and eIF4E both co-eluted. Quantification of the ratios of 
eIF4GII or myc to either protein shows that there is a reduction in PABP binding on nocodazole 
treatment, which is much more severe in the S384/392A mutant. Given the proximity of the PABP 
binding site to the phosphorylated region, it is perhaps unsurprising that there is some influence on 
the interaction. 
Subjecting the eluates to low percentage SDS-PAGE indicates that there is still some possible residual 
modification of the eIF4GII protein which contains the S384/392A mutant, indicating that there are 
other nocodazole-dependent phosphorylations elsewhere in the protein, as discussed below.  
  
Discussion 
Our work addresses some of the discrepancies that have been reported when observing cycling cells 
versus those that are arrested at various points in the cell cycle using pharmacological, nutritional or 
environmental treatments. The general consensus that there is a lack of protein synthesis during 
mitosis has come from the observation that treatment with colcemid, nocodazole or other 
microtubule disrupters (always for an extended period of time) results in a reduction in the 
incorporation of radiolabelled amino acids into precipitable proteins.10, 16  
However, our work following cycling cells after release from a double thymidine block shows that 
there are no substantial changes in overall protein synthesis rates as measured by incorporation of 
radiolabelled amino acids (Figure 1). This is coupled with our observations that initiation factors and 
ribosomal proteins co-localise with tubulin at various points during mitosis (Figure 2) suggesting that 
ongoing translation is indeed important for the process. Previous work examining the protein 
content of isolated CHO cell midbodies also revealed the presence of other ribosomal proteins and 
translation elongation factors,33 which supports our hypothesis that new proteins must be 
synthesised in order for proper abscission to proceed. Others have observed ribosomal protein S3 at 
the mitotic spindle34 and suggested that this is due to the protein having a function in a process 
other than translation. However, given our observation of other ribosomal proteins and initiation 
factors at this location, we suggest that involvement in protein synthesis is more likely. The 
observation that rpS3 knockdown causes arrest in metaphase,34 could also be interpreted as there 
being a key requirement for translation of mRNA during mitosis. Furthermore, our previous work 
examining the effects on cell morphology following knockdown of eIF4GI by shRNA19 showed an 
uncoupling of karyokinesis from cytokinesis, resulting in production of large cells with multiple nuclei, 
with similar results observed when eIF3e/Int-6 was depleted from cells.35 This phenotype is typically 
observed when similar experiments knock out or overexpress dominant negative forms of 
chromosomal passenger proteins (e.g. Aurora B, survivin36) suggesting these may be at least some of 
the particular components whose translation must be maintained during mitosis.  
As there are well characterised interactions between cytoskeletal components and ribosomal 
proteins, translation initiation factors and various mRNPs,37 it is therefore not surprising that using 
an agent such as nocodazole, which stops assembly of microtubules and also disassembles those 
previously made, should have such a drastic effect on protein synthesis. The link between cellular 
stress, the phosphorylation of eIF2 on Ser 51 of the α-subunit by one of four kinases and the 
consequential downregulation of translation rates has been comprehensively studied.38 As others 
have previously observed, there is robust phosphorylation of eIF2α following incubation with 
nocodazole, and we also show that other components of the translation initiation machinery are 
phosphorylated. As phosphorylation of eIF2α still occurs in PKR-/- MEFs (Figure S1), these data 
indicate a role for PERK in modification of eIF2. Unfortunately, PERK -/- MEFs did not arrest with 
nocodazole and consequently showed no change in eIF2α phosphorylation. 
The eIF4E-binding protein 4E-BP1 was observed to migrate as two forms, one corresponding to a 
completely unphosphorylated form (commonly referred to as the α form), whilst the other was 
retarded further in its migration compared to the gamma form which is phosphorylated at four sites 
(Thr 37, Thr 46, Ser 65 and Thr 70.24 This led us to attempt to pinpoint the further sites of 
modification but our results mutating Thr 82, Ser 83 and Ser 112 proved inconclusive. Advances in 
the sensitivity of proteomic instrumentation has led several groups to undertake large-scale 
phosphoproteomic analysis of cells (including HeLa cells) treated with nocodazole. For example, a 
recent publication involving HEK293 cells  found a further 11 sites of phosphorylation over the 
standard four, which included Ser 83 and Ser 112.39 Given that the shift in migration we observe 
does not correspond to such a drastic change in phosphorylation, which would result in multiple 
species on an immunoblot, it is possible that a single 4E-BP1 protein only undergoes some but not all 
possible modifications, in a particularly disorganised manner. In addition, how some 4E-BP1 protein 
remains in a completely unphosphorylated state is an as yet unanswered question. This could reflect 
some sort of protection in a compartment or complex which is inaccessible to the kinase(s) activated 
upon sustained incubation with nocodazole. It is also feasible that only pre-phosphorylated forms of 
4E-BP1 can then undergo further modifications, analogous to the observation that only 
phosphorylated 4E-BP1 is subjected to ubiquitination.40, 41  
Our investigations of the eIF4G paralogues were successful in identifying two sites of 
phosphorylation on eIF4GII at Ser 384 and Ser 392, through a combination of deletion analysis and 
unphosphorylatable serine-alanine mutations. While we have not conclusively identified the kinase 
responsible for this modification, it does appear likely to be Cdk1. The larger scale study of HEK293 
cells treated with nocodazole independently confirmed these modifications and also indicates 
several others, including one at Ser 382, one at Ser 644 (so may be evident when comparing Figure 
5E, lanes 8 and 9) and another at Ser 1560. A caveat of this previously published work is that, due to 
the experimental design, no distinction can be made between those residues which were 
phosphorylated in response to nocodazole or already modified. However, of particular interest was a 
phosphothreonine residue identified in the extended N-terminus, initiated from a CUG which is 
completely absent in eIF4GI proteins; the analysis could not determine whether Thr 64 or Thr 66 was 
the amino acid in question. This particular modification could account for the altered banding 
pattern observed above the main band in Figure 5E, lane 4. 
This comprehensive study did not identify any phosphopeptides in eIF4GI although an earlier 
independent study42 did find phosphorylation of this paralogue at both known sites (Ser 1186 and 
Ser 1188), together with another at Ser 1232. All these sites reside in the C-FAG fragment of eIF4GI 
and again could reflect the alteration in intensity of the two bands observed in Figure 5B, comparing 
lanes 5 and 6. 
The sites that we and others have identified in eIF4GII are between the regions known to bind PABP 
and eIF4E, which is notable as being the most poorly conserved region and lacks any currently 
unassigned binding partners in either paralogue (Figures 5A and 5D). Our previous work identified a 
nuclear localisation signal in eIF4GI further downstream of this region, which is not present in 
eIF4GII.17 Taken together these findings confirm that, despite initial experiments showing that the 
paralogues were functionally interchangeable, they are subject to several alternative regulatory 
controls. We have not been able to identify any clear changes in the composition of the eIF4F 
complex in response to these modifications, but they may be acting functionally somewhere else in 
the initiation pathway other than during the assembly of the mRNA-binding complex of 
eIF4E:eIF4G:PABP. 
It is clear from our work and the larger scale phosphoproteomic surveys that a number of initiation 
factors are modified by kinases following sustained nocodazole treatment, with the general 
consequence that translation rates are significantly reduced. However, as others have previously 
shown,16 a subset of messages is maintained in actively translating pools, with IRES-dependent 
translation postulated to be responsible for maintaining their translation while general cellular 
messages are inhibited. Different IRESs have alternative requirements for the canonical initiation 
factor machinery and it would be interesting to determine the eIF4G requirement and which 
particular modifications exert effects on IRES-driven translation. 
For a cell to progress through mitotis, a plethora of regulated phosphorylation and 
dephosphorylation events must occur.43 Our work has demonstrated increases in phosphorylation of 
key translation initiation factors following nocodazole treatment, which arrests cells at the G2/M 
boundary. However, when adding nocodazole for shorter times, these modifications were not 
observed. This suggests either that phosphorylation is a consequence of prolonged incubation which 
may activate further stress pathways, or that phosphorylation is extremely transient and only 
perceivable when given the opportunity to accumulate in stalled cells. While it is still not clear why 
these modifications are specifically required for mitotic progression, they do show that there is still 
much to learn about phosphorylation of initiation factors in different cellular conditions. Given that 
there is a considerable amount of research into using microtubule  and other cytoskeletal disruptors 
as chemotherapeutic agents,44-47 it is important to consider how these treatments may also be 
impinging upon gene expression at the level of translation initiation. 
 
Materials and Methods: 
Cell Culture and transient transfection Materials for tissue culture were from Invitrogen (UK) and 
foetal bovine serum (FBS) was from Labtech International (UK) or Invitrogen. HeLa (cervical cancer) 
cells were obtained from the ECACC (Salisbury, UK) and maintained in DMEM supplemented with 10% 
FBS at 37°C in a humidified atmosphere containing 5% CO2.  
Cell cycle synchronisation of HeLa cells was carried out following conditions as described by others.15 
Briefly, for the double thymidine block, cells were incubated for 16 hours with 2 mM thymidine, 
released for 8 hours, then synchronised for a further 16 hours with 2mM thymidine. For the 
thymidine/nocodazole treatments, the cells were incubated for 16 hours with 2mM thymidine, 
released for 6 hours, then incubated in 0.6µg/ml nocodazole for 20 hours.  
For transient transfection cells were seeded on 6 cm plates at a density of 1x105 cells per plate and 
24h later cells were transfected with 1 µg of pcDNA plasmid using GeneJuice (Merck, UK 
http://www.merckmillipore.com/united-kingdom/chemicals/genejuice-transfection-
reagent/EMD_BIO-70967/p_qI6b.s1OxjIAAAEjOhx9.zLX?PortalCatalogID=merck4biosciences), 
according to the manufacturer’s protocol. The transfection mixture was removed 24h later, and the 
cells were washed twice with PBS and further incubated in fresh media for 24h, until the addition of 
nocodazole . Preparation of cell lysates, and measurement of protein synthesis rates by 
incorporation of [35S] methionine into protein were carried out as previously described.19 Cell 
extracts were also prepared using M-PER reagent (Pierce 
http://www.piercenet.com/browse.cfm?fldID=06010420), supplemented with Halt phosphatase and 
protease inhibitor cocktail (Pierce http://www.piercenet.com/browse.cfm?fldID=E780097B-5056-
8A76-4EFC-572566DA6E04), as per the manufacturer’s instructions. 
Plasmids pcDNA plasmids containing N-terminal myc tags and C-terminal 3xFLAG tags have been 
described previously.8, 17, 19 For this study, cDNAs corresponding to portions of eIF4GI/II or 4E-BP1 
were subcloned from existing plasmids or HeLa cell cDNA using appropriate primers to maintain the 
open reading frame with the epitope tags, removing any endogenous stop codons where necessary. 
Site directed mutagenesis to generate alanine mutations of phosphorylation sites was performed 
using the Agilent Quikchange Lightning kit 
(http://www.genomics.agilent.com/en/product.jsp?cid=AG-PT-175&tabId=AG-PR-
1162&_requestid=640783) in accordance with the manufacturer’s instructions, using primers 
synthesised as directed by the Agilent Quikchange Primer design program. All sequences were 
confirmed by automated sequencing (Eurofins MWG or Beckman Coulter Genomics). 
FACS analysis At each time point, to ensure all cells both adherent and in suspension were harvested, 
all growth medium was removed and combined with a single PBS wash and the remaining cells 
which were subsequently harvested from the plate by dissociation with trypsin. Following 
centrifugation (1000xg for 5 min) and a single wash with ice-cold PBS, cells were fixed in 3ml of 
freshly made ice-cold 70% EtOH, 30% PBS and left at 4°C overnight. Each sample was washed twice 
in PBS before being resuspended in 500 µl PBS, containing 0.1 mg/ml RNase A to digest RNA and 
0.03 mg/ml Propidium Iodide solution to stain DNA, prior to incubation at RT for 30 min. Samples 
were analysed with a BD FACScanTM using appropriate filter sets. 
Immunoblotting Antibodies to eIF4GI, eIF4GII, eIF4A, eIF4E and PABP were prepared in house and 
have been previously described.17, 19 Antibodies to total 4E-BP1 
http://www.cellsignal.com/products/9452.html, phospho-4E-BP1 (Ser65) 
http://www.cellsignal.com/products/9451.html, phosphor-4E-BP1 (Thr70) 
http://www.cellsignal.com/products/9455.html, total eIF2α 
http://www.cellsignal.com/products/9722.html and phospho-eIF2α 
http://www.cellsignal.com/products/9721.html were from Cell Signaling Technology. Antibodies to 
myc (9E10) http://www.sigmaaldrich.com/catalog/product/sigma/m4439?lang=en&region=GB FLAG 
(M2) http://www.sigmaaldrich.com/catalog/product/sigma/f1804?lang=en&region=GB and actin 
http://www.sigmaaldrich.com/catalog/product/sigma/a2668?lang=en&region=GB were from Sigma-
Aldrich.  
Polysome gradients Sucrose density gradients to separate ribosomal subunits and those ribosomes 
associated with mRNAs were carried out as previously described.48 
Isolation of protein complexes from cell extracts m7GTP-Sepharose affinity isolation of eIF4E and 
associated factors, were carried out as previously described.19 Immunoprecipitation and Co-
immunoprecipitation experiments were carried out using the Pierce Co-Immunoprecipitation kit 
http://www.piercenet.com/browse.cfm?fldID=AB59D109-9690-4EAA-8521-E6C407156407, as per 
the manufacturer’s instructions, with anti-myc 9E10 or anti-FLAG M2 immobilised to the resin, 
depending on the experiment. 
Mass spec analysis FLAG-tagged immunoprecipitated protein was firstly separated by 1D-SDS-PAGE 
using a precast Novex Bis-Tris 4-12% gel http://www.invitrogen.com/site/us/en/home/Products-
and-Services/Applications/Protein-Expression-and-Analysis/Protein-Gel-Electrophoresis/Protein-
Gels/Novex-NuPAGE-SDS-PAGE-Gels/NuPAGE-SDS-PAGE-Bis-Tris-Gel.html. Following staining with 
Colloidal Coomassie blue, the gel band of interest was subjected to in-situ trypsin digestion using the 
method of Schevchenko et al.49 Peptide extracts were enriched for phosphopeptides using TiO2 
ProteaTips (Protea Biosciences, WV USA https://proteabio.com/products/SP-125) and used in 
accordance with the manufacturer’s instructions. Lyophilised peptide samples were re-suspended in 
50 mM sodium citrate pH 6.0 and loaded onto a reverse phase trap column (Symmetry C18, 5 µm, 
180 µm x 20mm, Waters Corporation http://www.waters.com/waters/en_GB/Symmetry-
Columns/nav.htm?cid=513219&locale=en_GB), at a flow rate of 5 µl/min and washed for 10 minutes 
with 3% acetonitrile containing 0.1% formic acid (buffer A) prior to the analytical nano-LC separation 
using a C18 Reverse phase column (HSS T3, 1.8 µm, 200mm x 75µm, Waters 
http://www.waters.com/waters/en_GB/HSS-%28High-Strength-
Silica%29Technology/nav.htm?cid=134618105).  Separation of peptides was achieved using a 
gradient of 0-50% buffer B (95% acetonitrile containing 0.1% formic acid (v/v)) at a flow rate of 300 
nl/min.  Eluted samples were sprayed directly into a Synapt G2-S mass spectrometer (Waters, 
Manchester, UK) operating in MSe mode. Data was acquired from 50 to 2000 m/z using alternate 
low and high collision energy (CE) scans. Low CE was 5V and elevated collision energy ramp from 15 
to 40V. Ion mobility was implemented prior to fragmentation using a wave velocity of 650 m/s and 
wave height of 40V. The lock mass Glu-fibrinopeptide, ((M+2H)+2, m/z = 785.8426) was infused at a 
concentration of 100 fmol/µl with a flow rate of 250 nl/min and acquired every 60 seconds. 
The raw mass spectra were submitted to ProteinLynx Global Server version 2.5.2 (Waters, 
Manchester, UK), and the data processed to generate reduced charge state and deisotoped 
precursor and associated product ion mass lists.  These mass lists were searched against the human 
UniProt protein sequence database (August, 2012) using the MASCOT search algorithm. A maximum 
of one missed cleavage was allowed for tryptic digestion with a fixed modification of 
carboxyamidomethylation of cysteines and variable modifications set to allow for oxidation of 
methionine and the phosphorylation of serine, threonine and tyrosine. 
Precursor ion and sequence ion mass tolerances were set at 20 ppm and 0.25 Da, respectively. The 
significance threshold for search results was set at p<0.05. 
Kinase assays Recombinant Cdk1/cyclinB1 was purchased from New England Biolabs 
https://www.neb.com/products/p6020-cdk1-cyclin-b, and the fragment of eIF4GII was obtained 
from an IP eluate and phosphorylated with 10 units of kinase for 30 minutes at 30°C in the presence 
of 200 µM ATP, in accordance with the manufacturer’s instructions. Enzyme activity was confirmed 
in parallel experiments by phosphorylation of eEF2K50 in the presence of 200 µM unlabelled ATP and 
1 µCi of [γ-32P] ATP. 
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Figure legends: 
 
Figure 1. Protein synthesis rates are not decreased during M phase when observing cycling 
synchronised cells. 
(A) Exponentially growing HeLa cells were maintained as an asynchronous population or 
synchronised at the G1/S boundary by double thymidine block and released for the number of hours 
indicated. Nuclei content of cells at each time point was determined by staining with propidium 
iodide and FACS analysis. 
(B) In parallel experiments translation rates were examined by pulsing cells with 35S Methionine for 
30 minutes prior to harvest.  Extracts were prepared, and the incorporation of radioactive 
methionine into protein (cpm/μg total protein) determined as described in the text. For the T/N 
sample, HeLa cells were blocked once in thymidine before being released then synchronised in M 
phase by incubation with the microtubule depolymerizing agent nocodazole for 19 hours. 
(C) Equal amounts of extract from (B) were subjected to SDS-PAGE and proteins transferred to PVDF. 
The membrane was then probed with the antibodies shown and visualized with secondary 
antibodies conjugated to HRP. 
Figure 2. The translation machinery costains with the microtubule network during different stages 
of mitosis and cytokinesis 
Cells released from a double thymidine block for 9 hours were fixed with 4% (w/v) 
paraformaldehyde and permeabilised with 0.1% (v/v) Triton X-100. Cells in different stages of mitosis 
and cytokinesis were examined by confocal microscopy, as determined by the positioning of 
microtubules or DNA (A-E). Upper panels show components of the translation machinery which were 
detected with rabbit polyclonal antibodies, as indicated, followed by an anti-rabbit secondary 
antibody conjugated to Alexa Fluor 555 (red). Lower panels show this signal merged with α-tubulin 
detected with a mouse monoclonal antibody conjugated to FITC (green) and DNA detected with 
DAPI (blue).   
Figure 3. Synchronisation with nocodazole inhibits translation and leads to substantial 
phosphorylation of components of the translation initiation machinery   
 (A) HeLa cells were either maintained asynchronously, or blocked once in thymidine before being 
released then synchronised in M phase by incubation with the microtubule depolymerizing agent 
nocodazole for 19 hours. As before, FACS analysis was used to determine nuclear DNA content.  
(B) Samples were subjected to sucrose density gradient centrifugation to determine the effect of 
incubation with nocodazole on polysome formation. Translation rates from these cells are shown as 
part of Figure 1(B), which confirm the large inhibition of translation, as determined by the reduction 
in 35S methionine incorporation. 
(C) Equal amounts of cell extracts from parallel samples were analysed by immunoblotting for the 
proteins indicated. To separate isoforms of eIF4G proteins that arise from alternative translation 
initiation, low percentage SDS-PAGE was used.  
(D) To determine whether shifts in migration of eIF4GI/II and 4E-BP1 were due to phosphorylation, 
extracts from asynchronous cells or cells which had been incubated with nocodazole for 19 hours 
were prepared. These were then incubated in the presence or absence of lambda protein 
phosphatase for 30 minutes before the treated extracts were separated by SDS-PAGE and 
immunoblotted for the indicated proteins. 
 
Figure 4. Robust phosphorylation of eIF2α does not occur following release from G2/M block and 
arresting synchronous cells with nocodazole has negligible effects on translation rates 
(A) HeLa cells were maintained asynchronously, subjected to a single thymidine nocodazole block, or 
incubated with the Cdk1 inhibitor RO3306 for 20 hours at a concentration of 9 μM to arrest cells at 
the end of G2. As this latter inhibitor is reversible, the drug was washed off and the cells progressed 
through mitosis, as observed by FACS analysis every 30 min. 
(B) Translation rates (obtained by pulsing for 15 min prior to harvest) were obtained from parallel 
experiments to (A) 
(C) Mobility shifts of eIF4GI and 4E-BP1 and the phosphorylation status of eIF2α were determined 
from cell extracts prepared in (C) by SDS-PAGE and immunoblotting with antibodies raised against 
standard or phosphor-epitopes, as indicated. 
(D) Cells were synchronised with a double thymidine block as before, then released into either 
medium which was either normal, supplemented with nocodazole at release, or supplemented with 
nocodazole 6 hours after release. FACS analysis of cells at the timepoints shown was used to show 
the arrest in G2/M in the cells incubated with nocodazole. 
(E) The amount of incorporation of [35S] methionine into protein for the 15 minutes prior to harvest 
was determined from parallel experiments to (D) as previously described. 
(F) As before, cell extracts from parallel experiments to (D) were made and subjected to SDS-PAGE 
and immunoblotting to show the phosphorylation status of eIF2α and 4E-BP1 in the three different 
treatments. 
(G) In an attempt to determine the novel phosphorylation site of 4E-BP1 that is detected following 
nocodazole treatment, the open reading frame of human protein was inserted into a vector, in 
frame with an N-terminal myc-tag and C-terminal 3xFLAG tag. Further variants were constructed 
where putative phosphorylation sites (S83 and S112) were mutated to alanine either singly or in 
combination. The four variants were then transfected into HeLa cells and either maintained 
asynchronously or treated with nocodazole for 19h. Cell extracts were prepared and the migration of 
the exogenous proteins determined by SDS-PAGE, detected with anti-FLAG antibody. 
(H) As for (G) mutants of 4E-BP1 were prepared where putative phosphorylation sites (T82 and S83) 
were mutated to alanine. After transfection into HeLa cells and nocodazole treatment as before, 
migration of FLAG-tagged proteins was examined by immunoblotting. 
Figure 5. Deletion analysis of eIF4G proteins reveals two novel phosphoserine sites in eIF4GII 
(A) A schematic representation of eIF4GI, showing the alternative AUG translation initiation sites (f 
through a) and the caspase-3 cleavage sites used to generate deletion fragments of this protein. 
Numbering conforms to the longest isoform as independently identified by others 20, 21. Each cDNA 
was inserted into a vector containing an N-terminal myc-tag and C-terminal 3xFLAG tag to enable 
detection. 
(B) Plasmids containing cDNAs representing the three fragments of apoptotic cleavage of eIF4GI 
(FAGs) were transfected into HeLa cells either untreated or incubated with nocodazole for 19h. Any 
changes in migration of the fragments due to the presence of nocodazole was determined by SDS-
PAGE and immunoblotting using anti-FLAG antibody to detect fragment expression. 
(C) Further deletion fragments of N-FAGf were constructed as before to delineate regions likely to be 
phosphorylated, these were transfected into HeLa cells and migration in the presence or absence of 
nocodazole was examined. 
(D) Deletion fragments of the N-terminus of eIF4GII were constructed as before, in order to map the 
phosphorylation site(s) of this protein. The amino acid numbering conforms to the CUGb initiated 
isoform previously identified by our group 8, which extends the open reading frame N-terminally 
from the initially published AUG. 
(E) Migration of the N-terminal fragments was examined following treatment with nocodazole for 
19h, with proteins detected with anti-FLAG antibody. 
(F) Further subfragments were made of the eIF4GII open reading frame, as indicated in (D), and their 
migration in cells treated with nocodazole determined as before. 
Figure 6. Identification of phosphorylation of eIF4GII at S385 and S389 by Cdk1, and consequences 
for initiation factor complex formation 
(A) Mass spectroscopy was used to identify phosphorylation of two serine residues (384 and 392) 
within the MSGG-APPT fragment of eIF4GII following immunoprecipitation of the fragment from 
cells treated with nocodazole. The sites are shown in bold and underlined, and the surrounding 
sequences were aligned with eIF4GI using CLUSTALW, showing the poor conservation of this 
particular region of the protein. The site of PABP binding is shown in grey, with a dashed underline. 
The symbols * : and . respectively denote identical  residues, or conserved and semi-conserved 
substitutions in the alignment.  
(B) Ser-Ala mutants, either single or in combination, of the MSGG-APPT fragment of eIF4GII were 
made and inserted into the myc-3xFLAG vector as before. Cells transfected with these vectors were 
incubated with or without nocodazole and migration of the proteins examined as before. 
 (C) Prediction software (GPS 2.1.2) indicated that likely kinases responsible for this phosphorylation 
were p38 MAPK or Cdk1. Therefore cell extracts were made from cells transfected with MSGG-APPT 
that had been incubated with or without nocodazole and cell permeable kinase inhibitors. These 
would either block p38 MAPK signalling (SB202190) or Cdk1 signalling (RO3306). Migration of the 
eIF4GII fragment was determined as previously described. 
(D) To confirm the results from panel (C), immunoprecipitated MSGG-AAPT protein was incubated in 
the presence of recombinant Cdk1/cyclin B and ATP. This was run alongside a positive control of 
extract from cells treated with or without nocodazole. 
(E) To determine whether the novel phosphorylation sites have any influence on the interactions of 
eIF4GII with other components of the translation initiation factor machinery, the S384/392A double 
mutant was introduced into the full length eIF4GII CUGb ORF. This vector contains an N-terminal 
myc tag, and therefore exogenous eIF4GII could be immunoprecipitated from transfected cells which 
had been incubated with nocodazole. The left hand panel shows the levels of endogenous proteins 
as determined by SDS-PAGE and immunoblotting, and the right hand panel shows the eluate from a 
co-immunoprecipitation where myc-9E10 antibody had been captured on agarose resin. 
Figure S1. PKR is not responsible for phosphorylation of eIF2α and hyperphosphorylation of 
4E-BP1 is mTORC1-independent. 
Mouse embryonic fibroblasts from PKR–/– animals (a kind gift from Prof. C. Weissmann) were 
incubated with thymidine for 16 hours, released for 4 hours, preincubated with various kinase 
inhibitors for 1 hour, then incubated without (left panel) or with nocodazole (right panel) for 16 
hours. 
Phosphorylation of eIF2α and modification of 4E-BP1 still occurred in cells treated with nocodazole 
alone. These events are not observed in cells treated with U0126 or RO-3306, but these inhibitors 
are known to arrest cells in G2, therefore the cells did not progress to M phase. The upwards shift of 
4E-BP1 in the presence of nocodazole is still observed in cells treated with Rad001, suggesting 
mTORC1 signalling is not involved in this modification. 
Figure S2. Raw mass spectra of eIF4GII phosphopeptides.  
Cells were transfected with a pcDNA plasmid expressing the eIF4GII MSGG-AAPT fragment (Figure 
5D), respectively tagged at the N- and C-termini with myc and 3XFLAG epitope tags. Cell extracts 
were prepared from control asynchronous cells and cells treated with nocodazole as before. The 
extracts were subjected to immunoprecipitation with an anti-FLAG M2 monoclonal antibody and the 
eluted proteins were separated by SDS-PAGE. Coomassie staining was used to visualise the eluted 
proteins and the bands that were present only in the nocodazole treated lane (as per Figure 5F) 
were excised, eluted and subjected to mass spectroscopy to identify phosphopeptides. 








